摘要
目的:研究帕立骨化醇与骨化三醇对继发性甲状旁腺功能亢进症的治疗效果及对安全性的影响。方法:选取笔者所在医院2016年1月-2019年1月收治的90例继发性甲状旁腺功能亢进症患者,利用等距随机抽样法将其分为对照组及观察组,各45例。对照组采取骨化三醇治疗,观察组采取帕立骨化醇治疗,比较两组临床治疗效果、安全性。结果:治疗前两组全段甲状旁腺激素、碱性磷酸酶、血钙、血磷水平比较,差异均无统计学意义(P>0.05);治疗后全段甲状旁腺激素、碱性磷酸酶、血磷均较治疗前降低,血钙较治疗前升高,差异均有统计学意义(P<0.05),且观察组各指标均优于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,治疗满意度高于对照组,差异均有统计学意义(P<0.05)。结论:相较于骨化三醇,帕立骨化醇在继发性甲状旁腺功能亢进症的治疗中效果更佳,安全性更高,可作为优选用药推广使用。
Objective:To study the efficacy and safety of Parecalcitol and Calcitriol in the treatment of secondary hyperparathyroidism.Method:A total of 90 patients with secondary hyperparathyroidism admitted in our hospital from January 2016 to January 2019 were selected.They were divided into the control group and the observation group by isometric random sampling method,with 45 cases in each group.The control group was treated with Calcitriol,and the observation group was treated with Palicalcitol.The clinical efficacy and safety of the two groups were compared.Result:There were no significant differences in the levels of whole parathyroid hormone,alkaline phosphatase,blood calcium and blood phosphorus between the two groups before treatment(P>0.05).After treatment,the levels of whole parathyroid hormone,alkaline phosphatase and blood phosphorus were lower than those before treatment,and the levels of blood calcium were higher than those before treatment,the differences were statistically significant(P<0.05),and the indexes in the observation group were better than those in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the treatment satisfaction was higher than that in the control group,the differences were statistically significant(P<0.05).Conclusion:Compared with Calcitriol,Palicalcitol is more effective and safe in the treatment of secondary hyperparathyroidism,and can be widely used as an optimal drug.
作者
丘宝珍
QIU Baozhen(Meizhou People’s Hospital,Meizhou 514031,China)
出处
《中外医学研究》
2019年第30期14-16,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH